Serial determination of CEA and CA 15.3 in breast cancer follow-up: An assessment of their diagnostic accuracy for the detection of tumour recurrences

Biomarkers

Volumn 14, Issue 2, 2009, Pages 130-136

  Mariani, Luigi ^a   Miceli, Rosalba ^a   Michilin, Silvia ^b   Gion, Massimo ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b IRCCS SAN CAMILLO HOSPITAL   (Italy)

Author keywords

Breast cancer; CA 15.3; CEA; Decision criteria; Sensitivity; Specificity

Indexed keywords

CA 15-3 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; MUCIN 1;

AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER RECURRENCE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE MARKER; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; SENSITIVITY AND SPECIFICITY; YOUDEN INDEX; BLOOD; BREAST TUMOR; CLINICAL TRIAL; IMMUNOLOGY; MULTICENTER STUDY; PROSPECTIVE STUDY; TUMOR RECURRENCE;

BREAST NEOPLASMS; CARCINOEMBRYONIC ANTIGEN; HUMANS; MUCIN-1; NEOPLASM RECURRENCE, LOCAL; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY;

EID: 66149140661     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.1080/13547500902770090     Document Type: Article

References (26)

1. Cohen A, Doveh E, Umansky T. 2001. How to assess the relative range of two consecutive laboratory measurements to monitor patients. J Biopharm Stat 11:177-191.
2. DeLong ER, Vernon WB, Bollinger RR. 1985. Sensitivity and specificity of a monitoring test. Biometrics 41:947-958.
3. Emir B, Wieand S, Su JQ, Cha S. 1998. Analysis of repeated markers used to predict progression of cancer. Stat Med 17:2563-2578.
4. Fraser CG. 2004. Inherent biological variation and reference values. Clin Chem Lab Med 42:758-764.
5. Fukuda I, Vamakado M, Kiyose H. 1998. Influence of smoking on serum carcinoembryonic antigen levels in subjects who underwent multiphasic health testing and services. J Med Syst 22:89-93.
6. Gion M, Cappelli G, Mione R, Vignati G, Fortunato A, Saracchini S, Biasioli R, Gulisano M. 1993. Variability of tumor markers in the follow-up of patients radically resected for breast cancer. Tumour Biol 14:325-333.
7. Gion M, Cappelli G, Mione R, Pistorello M, Meo S, Vignati G, Fortunato A, Saracchini S, Biasioli R, Giulisano M. 1994. Evaluation of critical differences of CEA and CA 15.3 levels in serial samples from patients operated for breast cancer. Int J Biol Markers 9:135-139.
8. Gion M, Barioli P, Mione R, Cappelli G, Vignati G, Fortunato A, Saracchini S, Biasioli R, Gulisano M. 1995. Tumor markers in breast cancer follow-up: A potentially useful parameter still awaiting definitive assessment. Forza Operativa Nazionale sul Carcinoma Mammario (FONCaM). Ann Oncol 6:31-35.
9. Gion M, Peloso L, Mione R, Vignati G, Fortunato A, Saracchini S, Biasioli R, Gulisano M, Cappelli G. 2001. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: A prospective study on 859 patients. Cancer J 7:181-190.
10. Gion M, Boracchi P, Dittadi R, Biganzoli E, Peloso L, Mione R, Gatti C, Paccagnella A, Marubini E. 2002. Prognostic role of serum CA15.3 in 362 node-negative breast cancers. An old player for a new game. Eur J Cancer 38:1165-1166.
11. Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, Somerfield MR, Hayes DF, Bast RC. 2007. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 25:5287-5312. (Pubitemid 350232263)
12. Laessig D, Nagel D, Heinemann V, Untch M, Kahlert S, Bauerfeind I, Stieber P. 2007. Importance of CEA and CA 15-3 during disease progression in metastatic breast cancer patients. Anticancer Res 27:1963-1968. (Pubitemid 46954709)
13. Molina R, Zanón G, Filella X, Moreno F, Jo J, Daniels M, Latre ML, Gimenez N, Pahisa J, Velasco M, Ballesta AM. 1995. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Breast Cancer Res Treat 36:41-48.
14. Molina R, Filella X, Alicarte J, Zanon G, Pahisa J, Munoz M, Farrus B, Ballesta AM. 2003. Prospective evaluation of CEA and CA 15.3 in patients with locoregional breast cancer. Anticancer Res 23:1035-1041. (Pubitemid 36750916)
15. Molina R, Barak V, Van Dalen A, Duffye MJ, Einarsson R, Gion M, Goike H, Lamerz R, Nap M, Sölétormos G, Stieber P. 2005. Tumor Markers in Breast Cancer - European Group on Tumor Markers Recommendations. Tumor Biol 26:281-293. (Pubitemid 41619458)
16. Nicolini A, Carpi A, Ferrari P, Anselmi L.1997a. Clinical use of tumor markers in the postoperative management of breast cancer patients: new concepts. Int J Biol Markers 12:181-186.
17. Nicolini A, Anselmi L, Michelassi C, Carpi A.1997b. Prolonged survival by 'early' salvage treatment of breast cancer patients: A retrospective 6-year study. Br J Cancer 76:1106-1111.
18. Nicolini A, Carpi A, Michelassi C, Spinelli C, Conte M, Miccoli P, Fini M, Giardino R.2003a. 'Tumour marker guided' salvage treatment prolongs survival of breast cancer patients: final report of a 7-year study. Biomed Pharmacother 57:452-459.
19. Nicolini A, Carpi A, Ferrari P, Pieri L.2003b. Utility of a serum tumour marker panel in the post-operative follow-up of breast cancer patients with equivocal conventional radiological examinations. Tumour Biol 24:275-280.
20. Park BW, Oh JW, Kim JH, Park SH, Kim KS, Kim JH, Lee KS. 2008. Preoperative CA 153 and CEA serum levels as predictor for breast cancer outcomes. Ann Oncol 19:675-681.
21. Queraltó JM. 2004. Intraindividual reference values. Clin Chem Lab Med 42:765-777.
22. Renehan AG, Egger M, Saunders MP, O'Dwyer ST. 2002. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. BMJ 324:813-825.
23. Riffenburgh RH, Cummins KM. 2006. A simple and general changepoint identifier. Stat Med 25:1067-1077.
24. Seregni E, Coli A, Mazzucca N. 2004. Circulating tumour markers in breast cancer. Eur J Nucl Med Mol Imaging 31:S15-S22.
25. Sölétormos G, Nielsen D, Schiøler V, Skovsgaard T, Dombernowsky P. 1996. Tumor markers cancer antigen 15.3, carcinoembryonic antigen, and tissue polypeptide antigen for monitoring metastatic breast cancer during first-line chemotherapy and follow- up. Clin Chem 42:564-575.
26. Sölétormos G, Nielsen D, Schiøler V, Mouridsen H, Dombernowsky P. 2004. Monitoring different stages of breast cancer using tumour markers CA 15-3, CEA and TPA. Eur J Cancer 40:481-486.